Abbvie Inc. | Date: 2015-02-04
The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF is detrimental, are also provided.
Abbvie Inc. | Date: 2015-06-26
In accordance with the teaching described herein, systems and methods are provided for prodding secure access to a software application on a computing device. The software application may include a security framework having a set of predetermined security requirements. Prior to enabling access to the software application by a user, the computing device may, (i) verify installation of a device security configuration profile on the computing device, wherein the device security configuration profile certifies that the software application includes the set of predetermined security requirements, (ii) receive identifying information from the user via a user interface, (iii) verify the identifying information with an authentication server, and (iv) based on a successful verification of the identifying information, receive and store a security token. Access to the software application on the computing device may be provided for a specified period identified by the security token.
Abbvie Inc. | Date: 2015-01-23
Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
Abbvie Inc. | Date: 2015-01-12
The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method.
Abbvie Inc. | Date: 2015-03-09
Proteins that bind both IL-17 and TNF are described along with their use in compositions and methods for treating, preventing, and ameliorating rheumatoid arthritis.